In last trading session, Myriad Genetics, Inc (NASDAQ:MYGN) saw 1.74 million shares changing hands with its beta currently measuring 1.80. Company’s recent per share price level of $10.41 trading at $0.16 or 1.56% at ring of the bell on the day assigns it a market valuation of $950.53M. That closing price of MYGN’s stock is at a discount of -181.46% from its 52-week high price of $29.30 and is indicating a premium of 10.09% from its 52-week low price of $9.36. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.22 million shares which gives us an average trading volume of 1.17 million if we extend that period to 3-months.
For Myriad Genetics, Inc (MYGN), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.53. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Myriad Genetics, Inc (NASDAQ:MYGN) trade information
Upright in the green during last session for gaining 1.56%, in the last five days MYGN remained trading in the green while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $10.41 price level, adding 9.0% to its value on the day. Myriad Genetics, Inc’s shares saw a change of -24.07% in year-to-date performance and have moved 0.68% in past 5-day. Myriad Genetics, Inc (NASDAQ:MYGN) showed a performance of -16.39% in past 30-days. Number of shares sold short was 4.91 million shares which calculate 3.61 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 26.5 to the stock, which implies a rise of 60.72% to its current value. Analysts have been projecting 11.5 as a low price target for the stock while placing it at a high target of 34. It follows that stock’s current price would drop -10.47% in reaching the projected high whereas dropping to the targeted low would mean a loss of -10.47% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around -69.92% while estimates for its earnings growth in next 5 years are of 42.20%.
Myriad Genetics, Inc (NASDAQ:MYGN)’s Major holders
Insiders are in possession of 2.17% of company’s total shares while institution are holding 103.96 percent of that, with stock having share float percentage of 106.26%. Investors also watch the number of corporate investors in a company very closely, which is 103.96% institutions for Myriad Genetics, Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at MYGN for having 15.15 million shares of worth $370.59 million. And as of 2024-06-30, it was holding 18.5369 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.06 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.314 of outstanding shares, having a total worth of $246.18 million.
